lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Sustainability == Hetero reports its ESG performance annually with reference to the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board( SASB), and the UN Global Compact. Environment Hetero leads its environment strategy with the stated goal of reaching net zero emissions by 2045. Interim environmental targets include 25% reduction in Scope 1 and Scope 2 emissions by 2030 (with 2022 as a baseline), a 30% increase in the use of renewable energy by 2030, and becoming a Zero Waste to Landfill company in the same year. According to the company’s FY2024-2025 Sustainability report, the company’s Scope 1 emissions were 3,12,435 tCO₂e and Scope 2 emissions were 2,95,020 tCO₂e, resulting in total Scope 1 and Scope 2 emissions of 6,07,455 tCO₂e. Emissions intensity for the year stood at 3.09 tCO₂e per million INR revenue, while biogenic emissions amounted to 72425 tCO₂e. The company also completed its first Scope 3 inventory, covering 13 categories and totalling 1,253,550 tCO₂e. 20% of Hetero’s total energy consumption came from renewable sources. The company recycled 343849 kilolitres of wastewater through Zero Liquid Discharge systems, and recycled 100% of non-hazardous waste, resulting in two sites (Annora and Jeedimetla) receiving Zero Waste to Landfill certification. Social Hetero’s social approach revolves around workforce wellbeing, diversity, inclusion, and occupational safety. As of FY2024-25, Hetero employed 18292 people directly and 10355 people through contract. Women made up 13.63% of direct workforce and 19.28% of contract workers.
== History == Trazodone was developed in Italy, in the 1960s, by Angelini Research Laboratories as a second-generation antidepressant. It was developed according to the mental pain hypothesis, which was postulated from studying patients and which proposes that major depression is associated with a decreased pain threshold. In sharp contrast to most other antidepressants available at the time of its development, trazodone showed minimal effects on muscarinic cholinergic receptors. Trazodone was patented and marketed in many countries all over the world, starting with Italy in 1972 and West Germany in 1977. It was approved by the Food and Drug Administration (FDA) in 1981 and was the first non-tricyclic or MAOI antidepressant approved in the US.
Dual polarisation interferometry is a surface-based technique for measuring the optical properties of molecular layers. When used to characterize protein folding, it measures the conformation by determining the overall size of a monolayer of the protein and its density in real time at sub-Angstrom resolution, although real-time measurement of the kinetics of protein folding are limited to processes that occur slower than ~10 Hz. Similar to circular dichroism, the stimulus for folding can be a denaturant or temperature.
In the early 2000s, 7-Eleven and Dentsu introduced a corporate mascot named Open-Chan (Open 小將), an extraterrestrial dog who wears a rainbow-shaped crown from a fictional planet known as Planet Open to be a "cartoon spokesperson" for the store chain in Taiwan. Open-Chan quickly grew in popularity among Taiwanese children soon after its initial debut. After Open-Chan's subsequent rise to prominence in Taiwan, the character was even introduced in Japan. The unique convenience store culture formed by President Chain Store (7-Eleven in Taiwan) has become a part of Taiwanese culture. 7-Eleven Taiwan also operates an MVNO called ibon mobile, which offers prepaid and postpaid SIM cards using the FarEasTone network.
The Soviet Union was an ethnically diverse country, with more than 100 distinct ethnic groups. The total population of the country was estimated at 293 million in 1991. According to a 1990 estimate, the majority of the population were Russians (50.78%), followed by Ukrainians (15.45%) and Uzbeks (5.84%). Overall, in 1989 the ethnic demography of the country showed that 69.8% was East Slavic, 17.5% was Turkic, 1.6% were Armenians, 1.6% were Balts, 1.5% were Uralic, 1.5% were Tajik, 1.4% were Georgian, 1.2% were Moldovan, and 4.1% were of other various ethnic groups. All citizens of the USSR had their own ethnic affiliation. The ethnicity of a person was chosen at the age of sixteen by the child's parents. If the parents did not agree, the child was automatically assigned the ethnicity of the father. Partly due to Soviet policies, some of the smaller minority ethnic groups were considered part of larger ones, such as the Mingrelians of Georgia, who were classified with the linguistically related Georgians. Some ethnic groups voluntarily assimilated, while others were brought in by force. Those who refused to assimilate would be mistreated and ostracized. Some ethnic groups suffered more than others, however some groups would be afforded better treatment than others. A person's quality of life was heavily influenced by their ethnicity. When the Bolsheviks first took power, they wanted to make it seem as if the ethnicities were equal. However, in most cases, Russians were generally preferred over other ethnicities.
Sources: en.wikipedia.org
=== Corrections of defect and deformity === Cancer – The excision of cancerous nasal skin can cause the loss of skin and internal support cartilage; such resections (surgical removal) usually are via the Mohs' chemosurgical technique. After removing the cancerous tissues, the reconstructive rhinoplasty will provide skin coverage using either skin grafts or pedicle flaps, (see Nasal Reconstruction, Paramedian Forehead Flap). If the resection of the cancerous skin leads to losing the nose tip, cartilage grafts can be used for support, and to prevent long-term distortion consequent to the force of the contracture of scar tissue.
This is a list of notable restaurant chains in the Philippines. A restaurant chain is a set of related restaurants with the same name in many different locations that are either under shared corporate ownership (e.g., McDonald's in the United States) or franchising agreements. Typically, the restaurants within a chain are built to a standard format through architectural prototype development and offer a standard menu and/or services.
==== Patron–client networks ==== Patron–client networks are defined by fluid interactions. They produce crime groups that operate as smaller units within the overall network, and as such tend towards valuing significant others, familiarity of social and economic environments, or tradition. These networks are usually composed of:
== Causes == Despite extensive investigation, the cause of IPF remains unknown. The fibrosis in IPF has been linked to cigarette smoking, environmental factors (e.g. occupational exposure to gases, smoke, chemicals or dusts), other medical conditions including gastroesophageal reflux disease, or to genetic predisposition (familial IPF). Certain environmental factors and exposures have been shown to increase the risk of IPF. Cigarette smoking is the best recognized and most accepted risk factor, and increases the risk of IPF by about twofold. Other environmental and occupational exposures such as exposure to metal dust, wood dust, coal dust, silica, stone dust, biologic dusts coming from hay dust or mold spores or other agricultural products, and occupations related to farming/livestock have also been shown to increase the risk for IPF. There is some evidence that viral infections may be associated with idiopathic pulmonary fibrosis and other fibrotic lung diseases.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.